Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

2024-518273-34-02 Protocol LARC-Tu Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 2 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol LARC-Tu

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 42
Countries 1
Sites 1

Malaria

Key facts

Sponsor
Universitaetsklinikum Tuebingen AöR
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Parasitic Diseases [C03]
Trial duration
2 Mar 2026 → ongoing
Decision date (initial)
2026-01-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Malaria

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Tuebingen AöR

Sponsor organisation
Universitaetsklinikum Tuebingen AöR
Address
Geissweg 3, Innenstadt Innenstadt
City
Tuebingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Prof. Dr. Peter Kremsner

Public contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Prof. Dr. Peter Kremsner

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 42 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Universitaetsklinikum Tuebingen AöR
Internal Medicine VII, Wilhelmstrasse 27, Innenstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-03-02 2026-03-12

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-04 Germany Acceptable
2026-01-23
2026-01-26
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-04 Germany Acceptable
2026-01-23
2026-03-04
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-12 Germany Acceptable
2026-01-23
2026-03-12
4 NON SUBSTANTIAL MODIFICATION NSM-3 2026-03-25 Germany Acceptable
2026-01-23
2026-03-25